Fundraising Fox

BrightSpec

Waltham, US · Founded 2012 · Delaware corporation · 26 employees on LinkedIn · 3 known investors

BrightSpec develops molecular rotational resonance (MRR) spectroscopy instruments and software that identify and quantify gas-phase molecules from complex mixtures without front-end separation. Its analytical platforms serve the pharmaceutical, chemical, and consumer goods industries for tasks such as structure validation, residual analysis, and raw material characterization.

Founders & leadership

RGRick Gordon
Rick GordoninCEO
WC
Walter ColsmanExecutive
JW
JAFFRAY WOODRIFFNamed on SEC filing
RL
ROBERT LLOYDNamed on SEC filing
TJ
THOMAS JONESNamed on SEC filing
DM
DAVID MCDANIELNamed on SEC filing

Board

JRJenny Rooke
Jenny Rookein𝕏Investor, DirectorManaging Director at Genoa Ventures
DCDavid Cash
David CashinBoard MemberPartner at Medvest Capital
DKDan Kidle
Dan KidleinBoard MemberManaging Partner at Arboretum Ventures
TG
Timothy GermannBoard director

Investors · 3

Reported raises · per SEC filings

Form D private placements

$17.1M disclosed across 5 rounds · 2017–2025

$3.9MraisedMay 2025 · 7 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jenny RookeDirector
  • Timothy GermannDirector
  • David CashDirector
  • Walter ColsmanExecutive Officer, Director
  • Dan KidleDirector
Offering amount
$11.1M
Amount sold
$3.9M
First sale
Apr 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$7.5MraisedDec 2022 · 24 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Walter ColsmanExecutive Officer, Director
  • David CashDirector
  • Terry DunlayDirector
  • Jenny RookeDirector
  • Dan KidleDirector
Offering amount
$15M
Amount sold
$7.5M
First sale
Dec 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$825KraisedOct 2021 · 7 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Terry DunlayDirector
  • George KastendikeDirector
  • Robert CreedenDirector
  • David CashDirector
  • Walter ColsmanExecutive Officer, Director
Offering amount
$1.5M
Amount sold
$825K
First sale
Oct 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$2.1MraisedMar 2019 · 5 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • ROBERT LLOYDExecutive Officer, Director
  • DAVID CASHDirector
  • JAFFRAY WOODRIFFDirector
  • WALTER COLSMANDirector
  • ROBERT CREEDENDirector
Offering amount
$2.7M
Amount sold
$2.1M
First sale
Feb 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$2.8MraisedAug 2017 · 3 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • JAFFRAY WOODRIFFDirector
  • ROBERT LLOYDExecutive Officer, Director
  • THOMAS JONESDirector
  • DAVID MCDANIELExecutive Officer, Director
Offering amount
$3M
Amount sold
$2.8M
First sale
Jun 2017
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Companies competing with BrightSpec for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 7 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$1M
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$1.6M
U.S. ArmyArmyPhase II2017$998.8K
National Science FoundationPhase II2016$746.1K
U.S. ArmyArmyPhase II2015$999.2K
National Science FoundationPhase I2015$149.9K
U.S. ArmyArmyPhase I2013$100K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does BrightSpec do?
BrightSpec develops molecular rotational resonance (MRR) spectroscopy instruments and software that identify and quantify gas-phase molecules from complex mixtures without front-end separation. Its analytical platforms serve the pharmaceutical, chemical, and consumer goods industries for tasks such as structure validation, residual analysis, and raw material characterization.
Who are BrightSpec's investors?
BrightSpec's investors include Arboretum Ventures, Genoa Ventures, Medvest Capital.
How much funding has BrightSpec raised?
BrightSpec has disclosed $17.1M raised across 5 rounds.
Where is BrightSpec headquartered?
BrightSpec is headquartered in Waltham, US.